PIK3CA represents a new molecular biomarker for HR+ HER2- BRCA‒advanced breast cancer in postmenopausal patients. In May 2019, the FDA approved the first PIK3 inhibitor for breast cancer patients with a Real Time (RT)-PCR‒based companion diagnostic (CDx) that can be used for both tissue and plasma samples.
Current breast cancer guidelines recommend molecular testing to be performed on specific request of the physician or in cases of hereditary breast cancer. To determine real-world laboratory readiness for PIK3CA adoption, we investigated the current use of molecular testing methodologies in 111 laboratories from 9 European countries.
PIK3CA testing adoption readiness for breast cancer in 9 European countries
PIK3CA testing adoption readiness for breast cancer in 9 European countries
18 December, 2020
